Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Papaverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.81 |
| ▸ | PDE3B | Q13370 | 9/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | USP2 | O75604 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | PDE4A | P27815 | 2/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.81 |
| ▸ | PDE2A | O00408 | 1/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.81 |
| ▸ | PDE5A | O76074 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Papaverine SCHEMBL29360983 | 0.90 | PDE10A (1.00) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL9551009 | 0.90 | PDE10A (1.00) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL34702 | 0.90 | PDE10A (1.00) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL29387160 | 0.90 | PDE10A (1.00) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL677440 | 0.89 | PDE10A (0.97) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL8691148 | 0.89 | PDE10A (0.97) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL29356374 | 0.89 | PDE10A (1.00) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL29696479 | 0.89 | PDE10A (1.00) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL28169527 | 0.89 | PDE10A (0.97) | PDE10APDE3APDE3BCYP3A4MAPK1 | |
| Papaverine SCHEMBL5500363 | 0.89 | PDE10A (1.00) | PDE10APDE3APDE3BCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203899-A1 | Drugs for incontinence | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| EP-1307184-A2 | DRUGS FOR INCONTINENCE | NICOX S.A. (FR) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002011707-A2 | DRUGS FOR INCONTINENCE | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203899-A1 | Drugs for incontinence | PDE3A, NOS1, PDE3B | PDE10A 42/4885PDE3A 1/4885PDE3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.